Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAWNASDAQ:CALANASDAQ:CXRXNASDAQ:NTHI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01$0.01$0.06▼$0.33N/AN/A34,287 shsN/ACALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.5616,027 shsN/ACXRX(CXRX)$0.19$0.19$0.19▼$1.80N/AN/A267,843 shs648,890 shsNTHINeonc Technologies$4.26-10.5%$6.52$4.11▼$25.00N/AN/A65,138 shs17,554 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%0.00%-24.76%-52.61%-72.30%CALACalithera Biosciences0.00%-95.00%-83.33%0.00%-99.20%CXRX(CXRX)0.00%0.00%0.00%0.00%0.00%NTHINeonc Technologies0.00%-24.06%-41.88%+425,999,900.00%+425,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACALACalithera Biosciences0.5956 of 5 stars0.01.00.04.50.60.00.0CXRX(CXRX)N/AN/AN/AN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/ACXRX(CXRX) 0.00N/AN/AN/ANTHINeonc Technologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/ACXRX(CXRX)N/AN/AN/AN/AN/AN/ANTHINeonc Technologies$79.99KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00N/AN/AN/AN/AN/AN/ACXRX(CXRX)N/AN/A0.00∞N/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest CXRX, AEHAW, CALA, and NTHI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NTHINeonc TechnologiesN/A-$2.10N/A-$2.10N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ACXRX(CXRX)N/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/ACALACalithera BiosciencesN/ACXRX(CXRX)6.09%NTHINeonc TechnologiesN/AInsider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/ACALACalithera Biosciences6.60%CXRX(CXRX)N/ANTHINeonc TechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableCXRX(CXRX)N/AN/AN/AOptionableNTHINeonc Technologies8N/AN/AN/ACXRX, AEHAW, CALA, and NTHI HeadlinesRecent News About These CompaniesNeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology ProgramsJune 6, 2025 | globenewswire.comNTHI NeOnc Technologies Holdings, Inc.June 1, 2025 | seekingalpha.comNeonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Acquires $14,780.00 in StockMay 24, 2025 | insidertrades.comNeonc technologies CFO Garnett Keithly acquires $976 in sharesMay 23, 2025 | investing.comInsider Buying: Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Buys 1,400 Shares of StockMay 20, 2025 | insidertrades.comWhy NeOnc Technologies Holdings, Inc.’s (NTHI) Stock Is Up 5.30%May 10, 2025 | aaii.comWhy NeOnc Technologies Holdings, Inc.’s (NTHI) Stock Is Down 5.06%April 23, 2025 | aaii.comNeOnc Technologies announces global patent portfolio totals 176April 16, 2025 | markets.businessinsider.comNeOnc Sees Share Price Fall Since Going PublicApril 15, 2025 | labusinessjournal.comNeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of ...April 15, 2025 | bakersfield.comNeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical MarketsApril 15, 2025 | markets.businessinsider.comNeOnc Technologies expects full enrollment in Phase 2a trial of NEO100-01April 15, 2025 | markets.businessinsider.comNeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical MarketsApril 15, 2025 | globenewswire.comNeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in SeptemberApril 14, 2025 | markets.businessinsider.comNeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in SeptemberApril 14, 2025 | globenewswire.comNeOnc Technologies appoints Heshmatpour as PresidentApril 10, 2025 | markets.businessinsider.comFrom Lab to Life: How NeOnc Technologies Accelerates Innovative Therapies to PatientsApril 10, 2025 | gsabusiness.comNeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New PresidentApril 10, 2025 | finance.yahoo.comNeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New PresidentApril 10, 2025 | globenewswire.comNeOnc Technologies announces NEO212 trial nears full enrollmentApril 8, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCXRX, AEHAW, CALA, and NTHI Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.01 0.00 (0.00%) As of 06/20/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Calithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.(CXRX) NASDAQ:CXRXNeonc Technologies NASDAQ:NTHI$4.26 -0.50 (-10.50%) As of 06/20/2025 04:00 PM EasternNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
